- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04248699
Lumenato Nutritional Supplement on Skin Appearance
August 16, 2020 updated by: LycoRed Ltd.
Open-Label Study to Assess the Impact of Lycored's Nutritional Supplement Lumenato on Skin Parameters in Healthy Women
This 12-week study is an open-label study assessing the perceived effectiveness of the Lycored Lumenato supplement on skin health and appearance.
Study Overview
Detailed Description
The purpose of this study is to evaluate perceived changes in skin health and appearance after taking the study product daily for 12 weeks.
The study product is a soft gel supplement containing tomato oil.
This an open-label study, meaning there is no placebo control arm for the study, and everyone enrolled in the study will receive the active study product.
Study Type
Interventional
Enrollment (Actual)
72
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
Orlando, Florida, United States, 32817
- o ObvioHealth
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
35 years to 55 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Female
Description
Inclusion criteria:
- Resides in the United States
- Generally healthy women between the ages of 35-55
- Fitzpatrick skin types 2 or 3
- Identifies as one of the following: Asian, White, Hispanic/Latino, or both White and Hispanic/Latino
- Type 2 on the Glogau Skin Classification scale
- Has expressed interest in improving skin health and appearance
- Willing and able to follow the procedures of the study
- Willing to refrain from changing their diet or lifestyle significantly for the duration of the study
- Able to understand the study requirements and activities in English, and provide informed consent
- Access to reliable internet service and smartphone in order to utilize the ClaimIt software/app needed to remotely participate in the study
Exclusion Criteria:
- Participants with Fitzpatrick skin types of 1, 4, 5 or 6
- Known allergies or sensitivity to tomato, latex and/or potato
- Current use or use within 1 month of study enrollment of hormonal therapies (including hormonal contraceptives)
- Current, regular use or regular use within 1 month of study enrollment of oral steroids; regular use defined as >10 consecutive days
- Chronic or relapsing inflammatory and/or allergic skin conditions such as atopic dermatitis, rosacea, psoriasis and alike including telangiectasias ("spider veins")
- Pregnant, lactating or breastfeeding women (within the last 6 months) or those planning to become pregnant during the study period
- Less than 2 years since diagnosis or treatment of skin cancer including basal cell carcinoma, squamous cell carcinoma, melanoma- excluding actinic keratosis
- Currently active herpes infections or currently on treatment for herpes infections
- History of facial keloids
- Current diagnosis of adult acne or currently on treatment for adult acne
- Recent (<6 months at enrollment) cardiovascular conditions such as stroke, transient ischemic attack (TIA), or myocardial ischemia/infarction, recently on treatment for congestive heart failure, or currently having vasculitis or vascular conditions
- On potent blood thinners such as low-molecular weight heparin (LMWH), rivaroxaban, apixaban, or other prescription blood thinners - excludes aspirin
- Holds a current diagnosis of diabetes mellitus type I or II
- Participants who have received facial irradiation within last year or are planning on undergoing facial irradiation during the study
- Chronic liver disease- excluding early stage non-alcoholic fatty liver disease (NAFLD)
- Chronic kidney disease or recent (<6 months at enrollment) acute kidney disease
- Participants who currently take supplements containing carotenoids, lutein, melatonin or tryptophan
- Participants with occupations or lifestyle that require significant daily exposure to the sun (defined as at least 1 hour of continuous outdoor sun exposure)
- Participants who have had a sunburn in the last 2 weeks
- Participants who use tanning salons or tanning products in the last 3 months
- Participants who plan to undergo invasive facial procedures (injections, chemical peeling, etc.) during the study or have undergone these procedures within 2 months prior to enrollment
- Change in oral supplements or medications targeting skin health within 2 months prior to enrollment
- Participants who are HIV positive
- Participants who are immunosuppressed
- Participants with a recent (<2 months prior to enrollment) diagnosis of a psychiatric condition
- Participants having chronic connective tissue disorder affecting the skin (e.g. Ehlers- Danlos syndrome, Marfan's Syndrome, Osteogenesis Imperfecta)
- Participants with auto-immune skin diseases (e.g. scleroderma, psoriasis, lupus, epidermolysis bullosa, bullous pemphigoid, temporal arteritis)
- Participants who have been prescribed retinoids treatment (<2 months prior to enrollment)
- Participants who meet either/or both of the following criteria with regards to smoking habits (smoking includes cigarettes, e-cigs, pipes, hookah, cigars):
- Who are current smokers (smoked at least 100 cigarettes, or tobacco/nicotine equivalent, in her lifetime) and who continue to use these products
- Who were former smokers (smoked at least 100 cigarettes, or tobacco/nicotine equivalent, in her lifetime, but who have quit smoking) who have smoked within the last year and/or were former smokers for 10 years
- Participants who drink more than 14 drinks per week (more than 2 drinks per night)
- Participants who use illicit or illegal drugs
- Participants who are regular users of cannabis substances or substances derived from cannabis such as CBD, CBD oils or balms, cannabis-containing edibles; vaping; smoking; hookahs.
- NOTE: regular use is defined as long stretches of inhaling or consuming these products over several months or longer. Occasional, but not weekly, use of products with small amounts of CBD-related compounds (e.g. waters with CBD infusions) are not considered regular use.)
- Participants who are planning a trip to the mountains or to a higher UV index region during the study period
- Any other medication, condition or disease that in the PI's opinion that may adversely affect the participant's ability to complete the study, substantially impact the study's integrity or may pose a significant risk to the participant
- Participants who are experiencing perimenopausal or menopausal symptoms
- Participants who have had a hysterectomy and/or both of their ovaries removed
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Lumenato Supplement
tomato oleoresin
|
tomato oleoresin obtained from yellow dry tomato pulp
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Participant perception of the improvement in skin health and appearance from Baseline to Week 12 using the questionnaire responses from FACE-Q™
Time Frame: 12 weeks
|
FACE-Q™ Satisfaction with Skin scale: gathers the participant perspective of their satisfaction or dissatisfaction with their facial skin using a 12-question scale.
Participants are asked to choose one of the following responses for each question: Very Dissatisfied (1), Somewhat Dissatisfied (2), Somewhat Satisfied (3) and Very Satisfied (4) for each 12 questions and the sum of scores (or mean of the completed items, in the event of an incomplete scale) gets converted into a score from 0 (worst) to 100 (best).
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Baseline Skin Questionnaire
Time Frame: 12 weeks
|
Participant perception of change or maintenance in a variety of skin health parameters over the course of the study using the subjective "Baseline Skin Questionnaire"
|
12 weeks
|
End of Study Product Questionnaire"
Time Frame: 12 weeks
|
Participant perception of the study product and study experience as assessed by the "End of Study Product Questionnaire"
|
12 weeks
|
Skin Update Questionnaire
Time Frame: 12 weeks
|
Participant perception of change or maintenance in a variety of skin health parameters over the course of the study using the subjective "Update Skin Questionnaire"
|
12 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse events (AEs) observed during the study, classified by the investigator as to severity, relationship to the study product/protocol, and seriousness
Time Frame: 14 weeks
|
classified by the investigator
|
14 weeks
|
Compliance to the daily use of the Lycored Lumenato supplement through monitoring within ClaimIt (Weekly e-Diary)
Time Frame: 12 weeks
|
Weekly e-Diary
|
12 weeks
|
Sustainability of effect after two weeks without supplementation as assessed by the Week 14 FACE-Q™ Satisfaction with Skin scale
Time Frame: 14 weeks
|
FACE-Q™ Satisfaction with Skin scale: gathers the participant perspective of their satisfaction or dissatisfaction with their facial skin using a 12-question scale.
Participants are asked to choose one of the following responses for each question: Very Dissatisfied (1), Somewhat Dissatisfied (2), Somewhat Satisfied (3) and Very Satisfied (4) for each 12 questions and the sum of scores (or mean of the completed items, in the event of an incomplete scale) gets converted into a score from 0 (worst) to 100 (best).
|
14 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Glogau RG. Aesthetic and anatomic analysis of the aging skin. Semin Cutan Med Surg. 1996 Sep;15(3):134-8. doi: 10.1016/s1085-5629(96)80003-4.
- Groten K, Marini A, Grether-Beck S, Jaenicke T, Ibbotson SH, Moseley H, Ferguson J, Krutmann J. Tomato Phytonutrients Balance UV Response: Results from a Double-Blind, Randomized, Placebo-Controlled Study. Skin Pharmacol Physiol. 2019;32(2):101-108. doi: 10.1159/000497104. Epub 2019 Mar 5.
- Havas F, Krispin S, Melendez-Martinez AJ, von Oppen-Bezalel L. Preliminary Data on the Safety of Phytoene- and Phytofluene-Rich Products for Human Use including Topical Application. J Toxicol. 2018 Apr 15;2018:5475784. doi: 10.1155/2018/5475784. eCollection 2018.
- Fitzpatrick TB. The validity and practicality of sun-reactive skin types I through VI. Arch Dermatol. 1988 Jun;124(6):869-71. doi: 10.1001/archderm.124.6.869. No abstract available.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
January 14, 2020
Primary Completion (ACTUAL)
June 8, 2020
Study Completion (ACTUAL)
July 8, 2020
Study Registration Dates
First Submitted
January 27, 2020
First Submitted That Met QC Criteria
January 29, 2020
First Posted (ACTUAL)
January 30, 2020
Study Record Updates
Last Update Posted (ACTUAL)
August 18, 2020
Last Update Submitted That Met QC Criteria
August 16, 2020
Last Verified
January 1, 2020
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- OBVIO-LYC-002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Skin
-
PharmanexCompletedSkin Elasticity | Beauty Drink Powder | Cosmetic Apparatus on Skin | Skin Dryness | Skin Moisture | Skin Evenness | Skin FirmnessChina
-
West Virginia UniversityMary Babb Randolph Cancer Center at West Virginia University Hospitals; West...RecruitingSkin Cancer | Skin Lesion | Skin Melanoma | Tumor SkinUnited States
-
Medical University of ViennaUnknownNon-melanocytic Skin Tumors | Melanocytic Skin TumorsAustria
-
National Taiwan University HospitalMinistry of Science and Technology, TaiwanUnknownSkin Cancer, Benign Skin Tumor, Inflammatory Skin DiseaseTaiwan
-
4Life Research, LLCCompletedSin Health | Skin Hydration | Skin Wrinkles | Skin Porphyrins | Facial Skin Red Spots | Facial Skin Red VasculatureUnited States
-
R2 DermatologyCompleted
-
TCI Co., Ltd.Completed
Clinical Trials on Lumenato
-
LycoRed Ltd.Completed
-
LycoRed Ltd.Withdrawn